Federal funding cuts threaten Colorado’s plan to reduce HIV infections
The Colorado Department of Public Health and Environment projected that new HIV diagnoses will total 482 in 2024 — virtually ...
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an ...
Trump administration weighs deep cuts to CDC’s HIV prevention program
LGBT+ groups and public health advocates warn against potential threats that could jeopardize progress and ‘set us back ...
WebMD12d
Antiretroviral Therapy (ART): Understanding HIV and AIDS Medications
What Are HIV/AIDS Medications? HIV medications can help lower your viral load, fight infections, and improve your quality of life. They can lower your chances of spreading HIV, but if you take ...
FierceBiotech11d
GSK posts data on HIV assets vying for roles in 6-month combo
GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its plans to create a six-month regimen are shaping up. ViiV, which is ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...